辉瑞以史上最大 ADC 并购案——430 亿美元收购 Seagen 后，艾伯维 101 亿、强生 20 亿、罗氏 10 亿，各家纷纷押注 ADC 赛道。今年依然热度不减，大冢制药 11 亿买入，罗氏再度加码 ADC 斥资 10 亿美元牵手 ...

Pfizer’s Mylotarg is back on the US market after a ... acute myeloid leukaemia patients whose tumours express the CD33 antigen, and adults and children two years and older with relapsed or ...

The committee voted 6-1 that Mylotarg in combination with chemotherapy has a favourable risk-benefit profile for patients with newly-diagnosed CD33-positive AML. The FDA is not bound to follow its ...

in which healthy transplant donor cells are genetically engineered by removing CD33, with the potential to enable targeted therapies such as Mylotarg and CD33-targeted CAR-T therapy post ...

Trem-cel is a shielded transplant in development for patients with AML and MDS, in which healthy transplant donor cells are genetically engineered by removing CD33, with the potential to enable ...